22-May-2026
Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
TipRanks (Thu, 21-May 7:41 PM ET)
Globe Newswire (Mon, 18-May 10:21 AM ET)
Globe Newswire (Mon, 18-May 9:26 AM ET)
Globe Newswire (Mon, 18-May 9:26 AM ET)
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Business Wire (Mon, 30-Mar 8:30 AM ET)
Market Chameleon (Tue, 10-Feb 4:51 AM ET)
Quince Therapeutics Announces Key Investor Events Ahead of Pivotal Phase 3 Results
Market Chameleon (Tue, 25-Nov 6:11 AM ET)
QNCX Highlights December 2025 Investor Events as Key Clinical Milestones Approach
Market Chameleon (Mon, 24-Nov 6:09 AM ET)
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Quince Therapeutics trades on the NASDAQ stock market under the symbol QNCX.
As of May 22, 2026, QNCX stock price climbed to $1.10 with 1,161,916 million shares trading.
QNCX has a beta of 2.56, meaning it tends to be more sensitive to market movements. QNCX has a correlation of 0.01 to the broad based SPY ETF.
QNCX has a market cap of $21.52 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, QNCX traded as high as $45.50 and as low as $.79.
The top ETF exchange traded funds that QNCX belongs to (by Net Assets): VXF, IWC.
QNCX has underperformed the market in the last year with a price return of -89.9% while the SPY ETF gained +29.1%. QNCX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.7% and -14.1%, respectively, while the SPY returned +8.4% and +1.1%, respectively.
QNCX support price is $1.01 and resistance is $1.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QNCX shares will trade within this expected range on the day.